Abstract
Objective: To establish the long term outcomes of risk stratified management of differentiated thyroid cancer (DTC).
Background: Guidelines for management of DTC lack a strong evidence base and expose patients to overtreatment. This prospective study of patients diagnosed with DTC between 1977-2012 describes the long term outcomes of a conservative risk stratified (AMES) management policy .
Methods: Outcomes were analysed around patient and tumour characteristics, primary intervention (surgery +/- radioiodine (RAI)), in terms of mortality, recurrence and reintervention.
Results: Median follow-up in 348 patients was 14 years: mean age 48 (range 10-
91) years, 257 (73.9%) female, 222 (68.3%) papillary cancer, tumour size 3.4 + 2.0 cm (mean + SD). 89 (25.6%) AMES high risk, 116 (33.3%) TNM stage III/IV and 16 (4.6%) had distant metastases. Primary surgery comprised lobectomy in 189 (54.3%): 11 (5.8%) patients had subsequent completion total thyroidectomy with cancer present in five. Primary nodal surgery was performed in 142 (40.8%) patients. 35 (13.5%) low and 43 (48.3%) high risk patients received RAI following initial surgery. Overall disease specific survival (DSS) was 92.1% at 10 years and 90.7% at 20 years. DSS at 20 years was 99.2% in low risk cases. AMES risk scoring predicted both survival and recurrence. Patients receiving RAI and AMES high risk were significantly associated with increased risk of death and recurrence.
Conclusions: Routine total thyroidectomy and RAI are not justifiable for low risk DTC. Treatment should be tailored to risk and AMES risk stratification remains a simple reliable clinical tool.
Background: Guidelines for management of DTC lack a strong evidence base and expose patients to overtreatment. This prospective study of patients diagnosed with DTC between 1977-2012 describes the long term outcomes of a conservative risk stratified (AMES) management policy .
Methods: Outcomes were analysed around patient and tumour characteristics, primary intervention (surgery +/- radioiodine (RAI)), in terms of mortality, recurrence and reintervention.
Results: Median follow-up in 348 patients was 14 years: mean age 48 (range 10-
91) years, 257 (73.9%) female, 222 (68.3%) papillary cancer, tumour size 3.4 + 2.0 cm (mean + SD). 89 (25.6%) AMES high risk, 116 (33.3%) TNM stage III/IV and 16 (4.6%) had distant metastases. Primary surgery comprised lobectomy in 189 (54.3%): 11 (5.8%) patients had subsequent completion total thyroidectomy with cancer present in five. Primary nodal surgery was performed in 142 (40.8%) patients. 35 (13.5%) low and 43 (48.3%) high risk patients received RAI following initial surgery. Overall disease specific survival (DSS) was 92.1% at 10 years and 90.7% at 20 years. DSS at 20 years was 99.2% in low risk cases. AMES risk scoring predicted both survival and recurrence. Patients receiving RAI and AMES high risk were significantly associated with increased risk of death and recurrence.
Conclusions: Routine total thyroidectomy and RAI are not justifiable for low risk DTC. Treatment should be tailored to risk and AMES risk stratification remains a simple reliable clinical tool.
| Original language | English |
|---|---|
| Pages (from-to) | 283-291 |
| Number of pages | 9 |
| Journal | The Surgeon |
| Volume | 16 |
| Issue number | 5 |
| Early online date | 9 Mar 2018 |
| DOIs | |
| Publication status | Published - Oct 2018 |
Bibliographical note
WL Craig was supported by a Cameron Research Fellowship, NHS Grampian. The University of Aberdeen Health Services Research Unit is supported by a core grant from the Chief Scientist Office of the Scottish Government Health and Social Care Directorate. There are no declared conflicts of interest.Keywords
- thyroid cancer
- surgery
- risk management
- conservative therapy
Access to Document
- Accepted Manuscript
© 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/